Abstract
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Highlights
In a cohort of BNT162b2 (Pfizer–BioNTech) Messenger RNA (mRNA) vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228)
We evaluated SARS-CoV-2-specific antibody responses after the first and second doses of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine in a large and diverse cohort of healthcare workers
We found that ACE2 binding inhibition was significantly higher among previously infected individuals than infection-naive individuals after a single vaccine dose (94.3% versus 37.3%, P < 0.001), with no between-group difference seen after the second dose
Summary
IgG(S-RBD) levels were only slightly lower in previously infected individuals at baseline when compared to infection-naive individuals who had received a single vaccine dose (log-median AU ml−1 (interquartile range, 6.0 (4.6, 6.9) versus 7.0 (6.3, 7.6)), P < 0.001). IgG(S-RBD) levels were not significantly different among previously infected individuals after a single dose and infection-naive individuals who had received two doses (10.0 (9.2, 10.4) versus 9.9 (9.4, 10.3), P = 0.92) (Fig. 1).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
